Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of ZyVersa Therapeutics, Inc. from 12 Dec 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
ZyVersa Therapeutics, Inc. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 12 Dec 2022 to 30 Sep 2025.
  • ZyVersa Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Sep 2025 was $20,657,218, a 760% decline year-over-year.
  • ZyVersa Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $9,406,690, a 91% increase from 2023.
  • ZyVersa Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $107,753,776, a 667% decline from 2022.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

ZyVersa Therapeutics, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $20,657,218 -$18,255,962 -760% 01 Jul 2025 30 Sep 2025 10-Q 19 Nov 2025 2025 Q3
Q2 2025 $2,211,317 +$542,719 +20% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q4 2024 $9,406,690 $1,424,661 +$12,509,907 +90% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $21,916,597 $2,401,256 +$501,632 +17% 01 Jul 2024 30 Sep 2024 10-Q 19 Nov 2025 2025 Q3
Q2 2024 $22,418,229 $2,754,036 +$83,571,283 +97% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $105,989,512 $2,826,737 +$1,764,264 +38% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $107,753,776 $13,934,568 -$13,114,500 -1599% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $94,639,276 $2,902,888 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $86,325,319 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $4,591,001 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $820,068 13 Dec 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY

ZyVersa Therapeutics, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $9,406,690 +$98,347,086 +91% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $107,753,776 -$93,706,169 -667% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $14,047,607 01 Jan 2022 12 Dec 2022 10-K 25 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.